Continued good compliance in Stayble Therapeutics´ Phase IIb study
Stayble Therapeutics AB ("Stayble" or the "Company") provides an update on the ongoing Phase IIb study. The company sees continued good compliance and approx. 70% of all patients have completed their 6-month follow-up, which is the primary endpoint of the study. Furthermore, Stayble is following the development in Russia and the assessment is that patients can conduct their follow-up visits without any difficulties.As previously reported, Stayble recently reached the important milestone of enrolling the last patient in the Phase IIb study. After the treatment, patients will return to the